Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label golimumab add-on study in biologic-naive rheumatoid arthritis with randomized IV versus SC golimumab remission strategy
NL-OMON36401Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of golimumab in rheumatoid arthritis (RA) (3 arms), sponsored by Merck & Co. Primary endpoints: Proportion achieving DAS28-ESR EULAR response, DAS28-ESR remission at start of month 11 and 1 more. Started Jan 2010; status: active, not recruiting.
02
Drugs
golimumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON36401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36401.